Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2025-05-07 00:00:00 ET · period of report 2025-05-06 · accession 0002065881-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-07 | 2025-05-06 | ARQT | Vairavan Latha | SVP CFO | A - Grant | $0.00 | +20.0K | 65.1K | +44% | $0 |
| D | 2025-05-07 | 2025-05-06 | ARQT | Vairavan Latha | SVP CFO | A - Grant | $0.00 | +60.0K | 60.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-06 | A | A | 20,000 | $0.00 | 65,104 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that will vest as to 25% of the RSUs on each annual anniversary of May 1, 2025 (the "Vesting Commencement Date"), beginning on May 1, 2026, subject to the Reporting Person's continued service through the vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2025-05-06 | A | A | 60,000 | $0.00 | 60,000 | D | $14.32 · — to 2035-05-06 | 60,000 Common Stock | (F2) The options will vest and become exercisable as to 1/48th of the shares on each monthly anniversary of May 6, 2025 (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through the applicable vesting date. |